Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Consistent with the tumor suppressive role of PRDM1, we identified MIR155HG and TERC to be transcriptionally downregulated by PRDM1 in two PRDM1-null NK-cell lines when it is ectopically expressed.
|
28468592 |
2017 |
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Finally, EBV super-enhancer-targeted IRF2 protected LCLs against Blimp1-mediated tumor suppression.
|
28494239 |
2017 |
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
This study identifies PRDM1 inactivation as a recurrent genetic defect in DLBCL cells and establishes PRDM1 as a potential tumor suppressor gene in DLBCL.
|
16424392 |
2006 |
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In support of its role as a tumor suppressor gene, the reconstitution of PRDM1 in PRDM1-null NK cell lines led to G2/M cell cycle arrest, increased apoptosis, and a strong negative selection pressure with progressive elimination of PRDM1-expressing cells, which was enhanced when IL-2 concentration is limiting.
|
22143801 |
2011 |
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In this review, we will summarize the role of BLIMP1 in normal cells, focusing on lymphoid cells, and on its function as tumor suppressor gene in lymphomas.
|
25115512 |
2015 |
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Our findings reveal that the downregulation of the tumour suppressor PRDM1 in EN-NK/T-NT samples is mediated by miR-223 and that PRDM1-positive staining might have prognostic value for evaluating the clinical outcome of EN-NK/T-NT patients.
|
24438193 |
2014 |
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Copy number analyses have highlighted potential tumor suppressor genes such as PR Domain Zinc Finger Protein 1 (PRDM1) and protein tyrosine phosphatase kappa (PTPRK) while next generation sequencing studies have identified recurrently mutated genes in pro-survival and anti-apoptotic pathways.
|
29966370 |
2018 |
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In this study, a mouse monoclonal antibody that recognizes PRDM1 was used to detail its distribution in normal human lymphoid tissue and in lymphoid neoplasms that correspond to different stages of B-cell differentiation.
|
15772984 |
2005 |
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
PRDM1/Blimp1, a master regulator of B-cell terminal differentiation, has been identified as a tumor suppressor gene in aggressive lymphomas, including diffuse large B-cell lymphoma (DLBCL).
|
26530011 |
2016 |
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Our results expand the spectrum of lymphoid malignancies in which PRDM1 may have a tumor suppressor role and identify an epigenetic event that likely contributes to the pathogenesis of BL.
|
25382611 |
2014 |
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Two alternative products of the gene exist, RIZ1, which contains a PR (PRDI-BF1-RIZ1) domain implicated in tumor suppressor function, and RIZ2, which is lacking this motif.
|
10688904 |
2000 |
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
These results demonstrate that BLIMP1 is a bona fide tumor-suppressor gene whose loss contributes to lymphomagenesis by blocking plasma cell differentiation.
|
21156281 |
2010 |
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Our results indicate that PRDM1 functions as a tumour suppressor in lung cancer.
|
28378641 |
2017 |
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
These findings point to a role for BLIMP1 as a tumor suppressor gene, whose inactivation may contribute to lymphomagenesis by blocking post-GC differentiation of B cells toward plasma cells.
|
16492805 |
2006 |
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
PRDM1 is a tumor suppressor that plays an important role in B and T cell lymphomas.
|
29760071 |
2018 |
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In vitro and in vivo experiments showed that that PRDM1 is a tumor suppressor gene in ALCL models, likely acting as an antiapoptotic agent.
|
24004669 |
2013 |
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
PRDM1 and FOXO3 are considered to play an important role in the pathogenesis of NK-cell neoplasms.
|
21690554 |
2011 |
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
PRDM1/Blimp-1, a master regulator for B cell terminal differentiation, is a putative tumor suppressor in diffuse large B cell lymphomas (DLBCL).
|
20651244 |
2010 |
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
For this reason, we focused on the tumor suppressor function of Blimp-1 on not only B but also T cell malignancies in this review.
|
20047096 |
2010 |
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Thus, similar to systemic diffuse large B-cell lymphomas, PRDM1 may be a tumor suppressor in some PCNSL and contribute to lymphomagenesis by impairing terminal differentiation.
|
18596541 |
2008 |
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
PRDM1/Blimp-1, a master regulator in terminal B-cell differentiation, has been recently identified as a tumor suppressor target for mutational inactivation in diffuse large B-cell lymphomas of the activated B-cell type.
|
18583325 |
2008 |
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The data led us to suggest that BLIMP1 may be a candidate B-NHL tumor suppressor gene.
|
8921366 |
1996 |
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
We further identified PRDM1, a tumor suppressor, was the target of miR-223-3p using microarray and luciferase assay.
|
31396355 |
2019 |
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Of interest, this deleted region contains four candidate tumor suppressor genes whose decreased expression has been confirmed at the mRNA level: PRDM1, ATG5, AIM1, and HACE1.
|
25203537 |
2014 |
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
PAX5 was virtually negative in all cases tested, whereas BLIMP1 was expressed in all tumors and XBP1 in 11 of 12.
|
23599149 |
2013 |